The UBA3 antibody is a crucial tool for studying the ubiquitin-like modifier-activating enzyme 3 (UBA3), a key component of the NEDD8-activating enzyme (NAE) complex. UBA3. in conjunction with APPBP1 (also known as NAE1), forms the heterodimeric E1 enzyme responsible for activating NEDD8. a ubiquitin-like protein. This activation is essential for the neddylation pathway, a post-translational modification process that regulates the activity of cullin-RING ligases (CRLs), which are critical for ubiquitination-mediated protein degradation. Dysregulation of neddylation has been implicated in various cancers, neurodegenerative diseases, and immune disorders, making UBA3 a target of therapeutic interest.
UBA3 antibodies are widely used in research to detect protein expression, localization, and interactions in cells or tissues. They enable techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate UBA3's role in cell cycle progression, DNA repair, and tumorigenesis. Studies have shown that UBA3 overexpression correlates with cancer proliferation and poor prognosis, highlighting its potential as a biomarker or drug target. Inhibitors targeting the NAE complex, such as MLN4924 (Pevonedistat), are under clinical investigation, further emphasizing the relevance of UBA3 in translational research. Researchers rely on high-specificity UBA3 antibodies to unravel molecular mechanisms and evaluate therapeutic interventions in disease models.